Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 1
2020 4
2021 13
2022 7
2023 3
2024 6
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
[Vaccines against COVID-19].
Fathi A, Mellinghoff SC. Fathi A, et al. Internist (Berl). 2021 Nov;62(11):1191-1201. doi: 10.1007/s00108-021-01164-0. Epub 2021 Oct 6. Internist (Berl). 2021. PMID: 34613428 Free PMC article. German.
The COVID-19 Vaccine Landscape.
Koch T, Fathi A, Addo MM. Koch T, et al. Among authors: fathi a. Adv Exp Med Biol. 2021;1318:549-573. doi: 10.1007/978-3-030-63761-3_31. Adv Exp Med Biol. 2021. PMID: 33973199 Review.
MVA-based SARS-CoV-2 vaccine candidates encoding different spike protein conformations induce distinct early transcriptional responses which may impact subsequent adaptive immunity.
Grewe I, Friedrich M, Dieck ML, Spohn M, Ly ML, Krähling V, Mayer L, Mellinghoff SC, Rottstegge M, Kraemer R, Volz A, Becker S, Fathi A, Dahlke C, Weskamm LM, Addo MM. Grewe I, et al. Among authors: fathi a. Front Immunol. 2024 Dec 19;15:1500615. doi: 10.3389/fimmu.2024.1500615. eCollection 2024. Front Immunol. 2024. PMID: 39749328 Free PMC article. Clinical Trial.
β-Propiolactone (BPL)-inactivation of SARS-Co-V-2: In vitro validation with focus on saliva from COVID-19 patients for scent dog training.
Pilchová V, Prajeeth CK, Jendrny P, Twele F, Meller S, Pink I, Fathi A, Addo MM, Volk HA, Osterhaus A, von Köckritz-Blickwede M, Schulz C. Pilchová V, et al. Among authors: fathi a. J Virol Methods. 2023 Jul;317:114733. doi: 10.1016/j.jviromet.2023.114733. Epub 2023 Apr 15. J Virol Methods. 2023. PMID: 37068591 Free PMC article. Review.
Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity.
Meyer Zu Natrup C, Tscherne A, Dahlke C, Ciurkiewicz M, Shin DL, Fathi A, Rohde C, Kalodimou G, Halwe S, Limpinsel L, Schwarz JH, Klug M, Esen M, Schneiderhan-Marra N, Dulovic A, Kupke A, Brosinski K, Clever S, Schünemann LM, Beythien G, Armando F, Mayer L, Weskamm ML, Jany S, Freudenstein A, Tuchel T, Baumgärtner W, Kremsner P, Fendel R, Addo MM, Becker S, Sutter G, Volz A. Meyer Zu Natrup C, et al. Among authors: fathi a. J Clin Invest. 2022 Dec 15;132(24):e159895. doi: 10.1172/JCI159895. J Clin Invest. 2022. PMID: 36301637 Free PMC article.
Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial.
Raadsen MP, Dahlke C, Fathi A, Hardtke S, Klüver M, Krähling V, Gerresheim GK, Mayer L, Mykytyn AZ, Weskamm LM, Zoran T, van Gorp ECM, Sutter G, Becker S, Haagmans BL, Addo MM; MVA-MERS-S_DF-1 Study group. Raadsen MP, et al. Among authors: fathi a. Lancet Infect Dis. 2025 Feb;25(2):231-242. doi: 10.1016/S1473-3099(24)00423-7. Epub 2024 Oct 7. Lancet Infect Dis. 2025. PMID: 39389076 Clinical Trial.
34 results